Editas test CRISPR to treat beta-thalassemia & sickle cell disease
Category: #health  By Nikita Chaurasia  Date: 2019-06-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Editas test CRISPR to treat beta-thalassemia & sickle cell disease

Editas Medicine Inc., a U.S.-based pharmaceutical company recently announced results from trial of two different CRISPR-Cas9 genome editing strategies, one targeting the beta-globin locus and the other targeting the erythroid enhancer, for treatment of beta-thalassemia & sickle cell disease. The data was presented by the company at the 24th Congress of the European Hematology Association in Amsterdam, report sources.

For the record, Editas Medicine Inc., is a leading genome editing pharmaceutical company, that focus on potential of CRISPR-Cas9 & Cas12a genome editing strategies in treatment of patients with serious diseases. The company aims to develop, manufacture & commercialize durable, transformative precision genomic medicines for wide-ranging class of diseases.

Charles Albright, Chief Scientific Officer, Editas Medicine, was reported to say that the pre-clinical results validating cells edited at the beta-globin locus repopulated all lineages of the blood system including RBC precursors & the high percentage of fetal hemoglobin expression, showed potential to treat beta-thalassemia & sick cell disease. Editing at the site continues to meet the company’s pre-clinical goals for making the medicine for durable induction of fetal hemoglobin & maintaining normal hematopoietic stem cell function, Albright added.

In this study, NBSGW mice (supports engraftment of human hematopoietic stem cells without irradiation) were reportedly given an infusion of human CD34+ cells which were edited either at beta-globin locus or the BCL11Ae. In vivo-derived erythroid cells from BCL11Ae and edited CD34+ hematopoietic stem cells had increased non-productive indels and reduced total indels, as compared to other lineages that have been tested (a phenomenon not observed with beta-globin locus editing). Also, further optimization of guide RNA & nuclease combinations led to fetal hemoglobin expression of approximately 40% in the beta-globin, locus-edited erythroid cells.

Based on the data, the pharmaceutical company has initiated IND-enabling activities for an experimental CRISPR medicine, EDIT-301. The drug is designed to durably treat beta-thalassemia & sickle cell disease by editing the beta-globin locus, cite sources.

Source credits: http://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-presents-pre-clinical-data-treatment-sickle-cell

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Japan’s SoftBank amid plans to invest in venture capital funds
Japan’s SoftBank amid plans to invest in venture capital funds
By Nikita Chaurasia

The conglomerate plans to mark its presence in Latin America by investing in venture capital funds, with a strategy to deploy nearly $500 million in five to 10 funds. SoftBank Group Corp., a multinational conglomerate based out of Tokyo, reportedly ...

TG Manufacturing acquires contract manufacturing firm TurnKey
TG Manufacturing acquires contract manufacturing firm TurnKey
By Nikita Chaurasia

TurnKey presently supplies a varied group of consumers in the industrial laboratory, defense and gaming industries among others. Using TGM’s advanced manufacturing technology, quality systems and global network and combining them with TurnKe...

Oxurion concludes enrollment of patients for THR-687 Phase 1 trial
Oxurion concludes enrollment of patients for THR-687 Phase 1 trial
By Nikita Chaurasia

12 patients with DME have enrolled into the study.   The results for the Phase 1 trial will be out by the end of 2019. Oxurion NV, a biopharmaceutical firm involved in the development of innovative treatments to preserve vision of diabetic...